Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Patnaik

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancerA Patnaik, E K Rowinsky, B K Tammara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
ESMO Open|December 9, 2022
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerE Garralda, A Sukari, N J Lakhani, et al.
Investigational New Drugs|May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancerR S Finn, D H Ahn, M M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|October 16, 2012
Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancerK N Chi, A Tolcher, P Lee, et al.
British Journal of Cancer|April 3, 2003
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesA W Tolcher, S L Gerson, L Denis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancerA Patnaik, E K Rowinsky, B K Tammara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumorsA W Tolcher, J C Bendell, K P Papadopoulos, et al.
International Journal of Clinical Pharmacology and Therapeutics|March 14, 2009
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumorsR L Oostendorp, J Loftiss, S Goel, et al.
ESMO Open|December 9, 2022
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancerE Garralda, A Sukari, N J Lakhani, et al.
Investigational New Drugs|May 23, 2018
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancerR S Finn, D H Ahn, M M Javle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
British Journal of Cancer|October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumoursK P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 8, 2017
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trialR Hui, E B Garon, J W Goldman, et al.
Pageof 4